What Ilaris treats.
- Cryopyrin-associated periodic syndromes (CAPS)
- Adult-onset Still’s disease
- Systemic juvenile idiopathic arthritis (SJIA)
- Familial Mediterranean fever
- Hyperimmunoglobulin D syndrome / mevalonate kinase deficiency
- TNF receptor-associated periodic syndrome (TRAPS)
The mechanism.
Ilaris (canakinumab) is a monoclonal antibody that binds and neutralizes interleukin-1 beta (IL-1β), a cytokine that drives the recurrent inflammation seen in periodic fever syndromes and certain autoinflammatory diseases. By blocking IL-1β, Ilaris reduces the frequency and severity of flares.
Your Ilaris infusion experience.
Ilaris is given as a subcutaneous injection every 4 to 8 weeks depending on the indication. Treatment is administered at our center with monitoring before and after the injection. Many patients see meaningful reduction in flare frequency and inflammatory markers within the first few doses.
Insurance & out-of-pocket cost.
Ilaris is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.